TY - JOUR
T1 - In search of antiepileptogenic treatments for post-traumatic epilepsy
AU - Saletti, Patricia G.
AU - Ali, Idrish
AU - Casillas-Espinosa, Pablo M.
AU - Semple, Bridgette D.
AU - Lisgaras, Christos Panagiotis
AU - Moshé, Solomon L.
AU - Galanopoulou, Aristea S.
N1 - Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2019/3
Y1 - 2019/3
N2 - Post-traumatic epilepsy (PTE) is diagnosed in 20% of individuals with acquired epilepsy, and can impact significantly the quality of life due to the seizures and other functional or cognitive and behavioral outcomes of the traumatic brain injury (TBI) and PTE. There is no available antiepileptogenic or disease modifying treatment for PTE. Animal models of TBI and PTE have been developed, offering useful insights on the value of inflammatory, neurodegenerative pathways, hemorrhages and iron accumulation, calcium channels and other target pathways that could be used for treatment development. Most of the existing preclinical studies test efficacy towards pathologies of functional recovery after TBI, while a few studies are emerging testing the effects towards induced or spontaneous seizures. Here we review the existing preclinical trials testing new candidate treatments for TBI sequelae and PTE, and discuss future directions for efforts aiming at developing antiepileptogenic and disease-modifying treatments.
AB - Post-traumatic epilepsy (PTE) is diagnosed in 20% of individuals with acquired epilepsy, and can impact significantly the quality of life due to the seizures and other functional or cognitive and behavioral outcomes of the traumatic brain injury (TBI) and PTE. There is no available antiepileptogenic or disease modifying treatment for PTE. Animal models of TBI and PTE have been developed, offering useful insights on the value of inflammatory, neurodegenerative pathways, hemorrhages and iron accumulation, calcium channels and other target pathways that could be used for treatment development. Most of the existing preclinical studies test efficacy towards pathologies of functional recovery after TBI, while a few studies are emerging testing the effects towards induced or spontaneous seizures. Here we review the existing preclinical trials testing new candidate treatments for TBI sequelae and PTE, and discuss future directions for efforts aiming at developing antiepileptogenic and disease-modifying treatments.
KW - Antiepileptogenesis
KW - Disease modification
KW - Inflammation
KW - Iron
KW - Neurodegeneration
KW - Outcomes
KW - Preclinical trial
KW - Tau
KW - Traumatic brain injury
UR - http://www.scopus.com/inward/record.url?scp=85049305403&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049305403&partnerID=8YFLogxK
U2 - 10.1016/j.nbd.2018.06.017
DO - 10.1016/j.nbd.2018.06.017
M3 - Review article
C2 - 29936231
AN - SCOPUS:85049305403
SN - 0969-9961
VL - 123
SP - 86
EP - 99
JO - Neurobiology of Disease
JF - Neurobiology of Disease
ER -